Welcome!

News Feed Item

2012: Sweeping Advances Made In MS Research

Part 1: Overview, Progress Toward Stopping MS   

NEW YORK, Dec. 26, 2012 /PRNewswire-USNewswire/ -- MS research continued to advance on many fronts in 2012. This year saw:

(Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO)

  • The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;
  • The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;
  • The discovery of what could be a target of the immune attack in people with MS may lead to new understanding of the disease and new treatment strategies;
  • The completion of the first human trial of an experimental therapy targeting myelin repair;
  • Progress in restoring functions using innovative rehabilitation techniques, including memory enhancement using a technique involving stories and imagery to solidify learning, and improving balance and mobility with specific exercises;and
  • Advances in uncovering MS triggering factors, bringing us closer to finding ways to prevent the disease; and many other advances pushing us closer to a world free of MS.

The National MS Society continues to propel research forward with a comprehensive strategy aimed at stopping MS, restoring function and ending MS forever (http://www.nationalmssociety.org/research/index.aspx):

In the world's largest meeting dedicated to MS research, over 7,000 scientists convened in Lyon, France to present findings at ECTRIMS (European Committee for Treatment and Research in MS). Over 1250 studies covering virtually every aspect of research were presented:

View videos on specific ECTRIMS topics http://www.youtube.com/playlist?list=PLnPWMdCPZiBbT4OEEunsWbzFTkWNoguQD&feature=addto

PROGRESS TOWARD STOPPING MS

The Society continued to invest in research to stop MS, including:

  • Funding of clinical trials:
    • Testing whether vitamin D, or the sex hormone estriol, or the probiotic approach of a sports drink containing parasite eggs, can reduce MS immune attacks
    • Determining if treatments available for other disorders, such as riluzole (a treatment for ALS or Lou Gehrig's disease) or phenytoin (a treatment for epilepsy), or the antioxidants lipoic acid or green tea extract, can protect the nervous system from damage.
    • Supporting a syndicate formed in the United Kingdom to conduct innovative clinical trials of neuroprotective drugs in secondary-progressive MS.
  • New projects focusing on discovering "biomarkers" to aid better diagnosis and treatment decisions;
  • Collaboration in a cross-disease drug screening initiative aimed at discovering the potential of compounds to stop nerve degeneration and protect the brain from harm;
  • In partnership with Merck Serono, Fast Forward provided funding for lab research to discover small molecules that can deliver therapies to areas of nervous system damage and protect against that damage in MS.

Other important 2012 results toward stopping MS include:

Treatment Pipeline

FDA Approves Oral Aubagio® (Teriflunomide, Genzyme, a Sanofi company) The once-daily pill was approved as a disease-modifying therapy for relapsing forms of MS. Aubagio is the second oral disease-modifying therapy approved for the treatment of MS, and it became available for prescription in October 2012 in the U.S. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6864

Two potential therapies are before FDA

Tysabri® label updated to include lab test to enhance treatment decisions –  The test detects antibodies to the JC virus and can help determine a person's risk of developing PML, a severe brain infection that has emerged in some people who have taken Tysabri (natalizumab, Biogen Idec and Elan). The test should enhance the ability of people with MS to weigh risks and benefits of this therapy. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=5887

Clinical trials discussed at ECTRIMS 2012 – Positive results from trials of statins (cholesterol-reducing medication) and Tysabri in progressive forms of MS, a new approach called AIN457 for treating relapsing MS, and results from phase II and III clinical trials of therapies were among results presented at ECTRIMS focusing on stopping MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7052

Phase II results of ocrelizumab in relapsing MS – Experimental ocrelizumab (Genentech), given intravenously, significantly reduced disease activity on MRI scans in a study of 218 people with relapsing-remitting MS. One person died due to brain edema; the relation of this death to the medication is unclear. Additional research, now going on in primary-progressive MS and relapsing-remitting MS, is needed to further determine this therapy's safety and benefits. http://www.nationalmssociety.org/research/research-news/news-detail/index.aspx?nid=5659

Another step toward personalized medicine in MS Harvard researchers discovered that differences in active genes that are detectable in blood samples may be used to group people with MS into categories that predict disease course and response to therapy. Further research is needed, but it represents an early step toward personalized medicine in MS. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6941

New approach to stopping MS Researchers at Northwestern University have developed an innovative strategy for selectively inhibiting the immune attack in MS using tiny "nanoparticles" that were able to reduce disease activity in mice. The team is now planning a phase I clinical trial of this new technology. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7126

Understanding MS

Possible target of immune attacks in some people with MS identified – An immune response to a protein – called "KIR4.1," which is found on several types of brain cells – was observed in the serum of 47% of people with MS. Further research is needed to confirm and understand these findings, which were the result co-funding by the National MS Society. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6619

MS Societies worldwide collaborate to stop MS progression The newly formed International Progressive MS Collaborative published a paper outlining challenges and identifying key research priorities to propel efforts to stop MS progression. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6847

Stress management reduces MS activity A 24-week stress management program reduced disease activity on MRI scans significantly more than in a control group, in a study at Northwestern University involving 121 people with relapsing MS. However, the benefits appeared to disappear after the weekly in-person stress management sessions were completed. Future studies should provide more clarity for optimizing the potential benefits of stress management. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=6629

Society launches project to change how MS disability and progression are measured This cross-sector collaboration has the goal of developing new or improved tools that will be able to track benefits of therapies more quickly in people so that new therapies to stop MS progression may be tested using better assessment tools that are accepted by drug regulatory agencies. http://nationalmssociety.org/news/news-detail/index.aspx?nid=6777

Researchers co-funded by the National MS Society discover possible mechanism for MS damage to nerve tissue – The University of California, San Francisco researchers found that a blood-clotting protein called fibrinogen may play an early role in triggering inflammation that damages nerve fibers in a mouse model of MS. This points to a role for fibrinogen in stimulating inflammation by cells called microglia. If confirmed, targeting the interaction of fibrinogen and microglia may prove to be a novel strategy for stopping MS damage in its tracks. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=7157

Save this date January 30, 2013, 2:00 – 3:00 p.m. ET and sign up for the live webcast, "From the Frontlines: New Avenues In MS Research for 2013." Visit the National MS Society website.

About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body.  Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 400,000 people in the U.S. and over 2.1 million worldwide.

About the National Multiple Sclerosis Society
The National MS Society addresses the challenges of each person affected by MS. To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move forward with their lives.  In 2011 alone, through its national office and 50-state network of chapters, the Society devoted $164 million to programs and services that assisted more than one million people. To move us closer to a world free of MS, the Society also invested $40 million to support more than 325 new and ongoing research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at www.nationalMSsociety.org.

SOURCE National Multiple Sclerosis Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...